BSTC BioSpecifics Technologies Corp

54.93
-0.53  -1%
Previous Close 55.46
Open 55.68
Price To Book 3.45
Market Cap 403,151,594
Shares 7,339,370
Volume 74,098
Short Ratio
Av. Daily Volume 48,157
Stock charts supplied by TradingView

NewsSee all news

  1. BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

    LYNBROOK, N.Y., Nov. 8, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class

  2. Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

    LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in

  3. BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

    LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
PDUFA date July 6, 2020.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 new data to be presented 2H 2019.
XIAFLEX
Uterine fibroids

Latest News

  1. BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

    LYNBROOK, N.Y., Nov. 8, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class

  2. Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

    LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in

  3. BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

    LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class